|Report Code: PP10222||Report Type: Mechanism of Action Reports||Pages: 300+||Available format:|
|Therapeutic Area(s):||Oncology | Immunology | Dermatology | Gastroenterology | Musculoskeletal | Neurology | Others|
IL-6 is transcribed by IL-6 gene that encodes a cytokine, which functions in inflammation and maturation of B cells. The IL-6 protein can induce fever in patients suffering from autoimmune diseases, thereby acting as endogenous pyrogens. The protein is mainly produced at the sites of acute and chronic inflammation, where it is secreted into the serum and induces a transcriptional inflammatory response through IL-6α receptor. IL-6 gene plays a significant role in wide variety of inflammation-associated disorders, including systemic juvenile rheumatoid arthritis. The role of IL-6 protein has been seen in various diseases such as cancer, schizophrenia, diabetes mellitus, systemic juvenile rheumatoid arthritis, asthma, and depression. The IL-6 inhibitors target the IL-6 receptors (IL-6Rs), thereby preventing the binding of IL-6 ligands to IL-6 receptors. Thus, inhibiting the entire IL-6 signal transduction.
Actmera (F. Hoffmann-La Roche Ltd.), Kevzara (Regeneron Pharmaceuticals Inc. and Sanofi-aventis Groupe), and Sylvant (Janssen Global Services LLC) are amongst the U.S. Food and Drug Administration (USFDA) approved medications targeting IL-6 signaling pathway and antagonizing its mechanism of action.
Positive clinical trial results and strategic decisions of companies to collaborate with other companies are also facilitating drug development in IL-6 inhibitors pipeline arena. Additionally, the issuance of patents helps in achieving different milestones in the form of grants and designations from regulatory bodies and institutes, including the U.S. Food and Drug Administration (USFDA), the European Medicines Agency (EMA), and the National Institutes of Health (NIH).
As of March 2019, the IL-6 inhibitors pipeline comprised 25+ drugs in different stages of development.
Some of the companies involved in the development of IL-6 inhibitors include F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., Sanofi-aventis Groupe, Janssen Global Services LLC, Novimmune SA, and UCB Pharma.
Some highlights of the report “Interleukin-6 (IL-6) Inhibitors – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments”, have been mentioned below: